Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | FADS1 | O60427 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12858928 | 0.74 | CYP11B1 (0.57) | CCR1CCR5CCR8HDAC6CYP3A4 | |
| SCHEMBL13127863 | 0.73 | AR (0.39) | PDK2 | |
| SCHEMBL16554646 | 0.72 | DYRK1A (0.50) | PDK2PIM1LRRK2 | |
| SCHEMBL16554797 | 0.72 | FYN (0.42) | PDK2 | |
| SCHEMBL9887864 | 0.71 | CYP3A4 (0.50) | CYP3A4PDK2 | |
| SCHEMBL15379161 | 0.70 | PDK2 (0.42) | CYP3A4PDK2ALOX5APLRRK2FEN1 | |
| SCHEMBL22530216 | 0.70 | KCNH2 (0.54) | PDK2ALOX5AP | |
| SCHEMBL30574243 | 0.70 | ALOX5AP (0.42) | ALOX5APPIM1HCRTR1HCRTR2LRRK2 | |
| SCHEMBL15782893 | 0.69 | FFAR1 (0.51) | PDK2ALOX5APPIM1LRRK2FEN1 | |
| SCHEMBL17051514 | 0.68 | CCR1 (0.75) | CCR1CCR5CCR8HDAC6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135591-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN-LA ROCHE INC. (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135591-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, LIPC, PNLIP | CCR1 3400/4885CCR5 4498/4885CCR8 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.